The effect of symbiotic supplement on patients with type 2 Diabetes

The effect of Symbiotic supplement and Placebo on Glycemic Control, Serum lipids profile and Microalbuminuria in Patients with Type 2 Diabetes: A Double Blinding, Randomized, Control Trials

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015072223284N1

Enrollment

Registered

2016-05-21

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. None-Insulin-dependent diabetea mellitus with renal complication

Interventions

Intervention 1: Intervention group: per day 500 mg capsule receptacle synbiotics (familact) duration 8 week. Intervention 2: control group: per day 1 capsule receptacle placebo duration 8 week.

Diagnosis

Placebo

Intervention group: per day 500 mg capsule receptacle synbiotics (familact) duration 8 week

control group: per day 1 capsule receptacle placebo duration 8 week

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who have BMI under 35, have microalbuminuria, are consent to participate in the study and are not pregnant or in lactation are included in the study. Exclusion criteria: Patients who use antibiotic drugs, don't use supplements or placebo more than 10 consecutive days, migrate or die are excluded in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Urea , Creatinine serum. Timepoint: In base line and end of the study. Method of measurement: Photometric.;TG,Chol,HDL,LDL. Timepoint: In base line and end of the study. Method of measurement: Photometric.;Albumin/Creatine (urine). Timepoint: In base line and end of the study. Method of measurement: Immuno-turbidimetric.;Fast blood glucose. Timepoint: In base line and end of the study. Method of measurement: Colorimetric.;HbA1c. Timepoint: In base line and end of the study. Method of measurement: HPLC.;Systolic and Diastolic Blood Pressure. Timepoint: In baseline and at the end of the study. Method of measurement: Digital Blood Pressure Monitor.;Height. Timepoint: In baseline and at the end of the study. Method of measurement: Non-stretched tape measure(Seca, Germany) to the nearest 0.1 cm.;Weight body. Timepoint: In baseline and at the end of the study. Method of measurement: An overnight fasting status, without shoes by the use of a digital scale (Seca, Germany).	—

Measure

Time frame

Urea , Creatinine serum. Timepoint: In base line and end of the study. Method of measurement: Photometric.;TG,Chol,HDL,LDL. Timepoint: In base line and end of the study. Method of measurement: Photometric.;Albumin/Creatine (urine). Timepoint: In base line and end of the study. Method of measurement: Immuno-turbidimetric.;Fast blood glucose. Timepoint: In base line and end of the study. Method of measurement: Colorimetric.;HbA1c. Timepoint: In base line and end of the study. Method of measurement: HPLC.;Systolic and Diastolic Blood Pressure. Timepoint: In baseline and at the end of the study. Method of measurement: Digital Blood Pressure Monitor.;Height. Timepoint: In baseline and at the end of the study. Method of measurement: Non-stretched tape measure(Seca, Germany) to the nearest 0.1 cm.;Weight body. Timepoint: In baseline and at the end of the study. Method of measurement: An overnight fasting status, without shoes by the use of a digital scale (Seca, Germany).

—

Secondary

Measure	Time frame
Daily recieved energy. Timepoint: In base line and at the end of the study. Method of measurement: recall 24 hour questionnaire.;Daily recieved carbohydrate. Timepoint: In base line and at the end of the study. Method of measurement: recall 24 hour questionnaire.;Daily recieved fat. Timepoint: In base line and at the end of the study. Method of measurement: recall 24 hour questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZarin Sadat Ebrahimi

Yazd Shahid sadoughi University of Medical Sciences

ebrahimizarin@gmail.com+98 37240373

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026